• CAS
  • |
  • C&EN
  • |
  • Journals
  • |
  • ACS

search site
Advanced Search »
  • Home
  • |
  • About CAS
    • CAS Media Library
    • CAS Quotes
    • Colors of Chemistry
    • 100th Anniversary Celebration
    • Careers at CAS
    • FAQs
    • Directions to CAS
    • Contact Us
  • |
  • Our Expertise
    • CAS Databases
    • Value Added Tools
    • Technical Service and Support
  • |
  • Solutions
    • Researchers
    • IP Professionals
    • Information Professionals
    • Academics
  • |
  • Products & Services
    • SciFinder
    • STN Family of Products
    • Science IP
    • CAS Client Services
    • CAS Document Detective Service
    • CD Products
    • Print Products
  • |
  • Support & Training
    • SciFinder
    • SciFinder Scholar
    • STN
    • STN Express
    • STN AnaVist
    • STN Viewer
    • STN on the Web
    • STN Easy
    • CAS Customer Care
  • |
  • News & Events
    • What's New
    • Press Room
    • News Releases
    • In the News
    • Trade Shows
  • CAS Science Spotlight Home
  • Most Requested Patent Families 4Q04-Chemistry and Related Science
  • What's New
  • About
Home   •   Spotlight  •  rlist4q04p  •  Most Requested Patent Families 4Q04-Chemistry and Related Science (3)
Most Requested Patent Families 4Q04-Chemistry and Related Science
spotlightlogo.gif

Following is one of the patent documents most requested by researchers using CAS electronic products.



CAS indexed 5 chemical substances from this document.
CAS subject entries for this document include: Mental disorder; Headache; Nerve, disease; and 10 additional concepts.

CAPLUS COPYRIGHT 2005 ACS on STN

TITLE: Preparation of topiramate sodium trihydrate as antiepileptic agents
INVENTOR(S): Almarsson, Orn; Remenar, Jules; Peterson, Matthew L.
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: U.S., 31 pp. CODEN: USXXAM
LANGUAGE: English
PATENT INFORMATION:
PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
---------------     ----   --------    --------------------   --------
US 6559293 B1 20030506 US 2002-232589 20020903 US 2003166581 A1 20030904 US 2002-295995 20021118 US 6699840 B2 20040302 WO 2003070738 A2 20030828 WO 2003-US4357 20030214 WO 2003070738 A3 20030925 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1485388 A2 20041215 EP 2003-742731 20030214 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 2004053853 A1 20040318 US 2003-637829 20030808 WO 2004060347 A2 20040722 WO 2003-US41642 20031229 WO 2004060347 A3 20041104 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

ABSTRACT:
The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhyd., or amorphous forms thereof, as well as pharmaceutical compns. and pharmaceutical unit dosage forms contg. the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhyd., and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compns. comprising them. The invention also encompasses methods of treating or preventing in vivo patients a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.

 

Updated 5/11/2007 11:41:17 AM
Home  |  About CAS  |  Our Expertise  |  Solutions  |  Products & Services  |  Support  |  News & Events
Copyright © 2008 American Chemical Society